Differential expression of IFN-γ, IL-4, IL-10, and IL-1β mRNAs in decalcified tissue sections of mouse lipopolysaccharide-induced periodontitis mandibles assessed by in situ hybridization

Y. Iwasaki,Y. Hara,T. Koji,Y. Shibata,P. Nakane,I. Kato

DOI: https://doi.org/10.1007/s004180050234

1998-03-17

Histochemistry and Cell Biology

Abstract:

What problem does this paper attempt to address?

Influence of C677T Polymorphism of 5,10-Methylenetetrahydrofolate Reductase on Methotrexate Toxicity

YAN Xu-yan,XU Dong-hang

DOI: https://doi.org/10.3321/j.issn:1001-2494.2007.01.020

2007-01-01

Abstract:OBJECTIVE To investigate the relationship between the mutation of 5,10-methylenetetrahydro-folate reductase(MTHFR) gene 677 C→T and the adverse drug reaction of methotrexate(MTX) in patients with rheumatoid arthritis((RA).)METHODS A total of 210 patients with RA were divided into MTX group,MTX+sulphasalazine(SASP) group,MTX+ Leflunomide(LEF) group and LEF+SASP group.100 healthy subjects were chosed as control group. PCR-restrictive fragment length polymorphism(RFLP) analysis was conducted to test mutation.The clinical measurements,laboratory measurements,the Disease Activity Score(DAS) were evaluated during 48 weeks.And the cases of adverse drug reaction(ADR) were also collected.RESULTS No difference was tained the three with genotypes of MTHFR.The frequencies of adverse drug reaction of patients with heterozygous(CT),and homozygous(TT) mutation in MTX,MTX+SASP,MTX+LEF was more than that without mutation(CC).Patients with heterozygous or homozygous mutation in the MTHFR gene induced a significantly higher plasma homocysteine at week 48,compared with those without mutation.But there was no statistical significance observed amonc CT,TT and CC when in LEF+SASP group.CONCLUSION MTHFR gene C677T mutation is probably one of the genetic risk factors for adverse drug reaction of MTX.
Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients – identification of novel single nucleotide polymorphism: Cross-sectional study

Qassim Mahdi Mutlak,Ali Abdulhussain Kasim,Ali Saleh Aljanabi

DOI: https://doi.org/10.1097/md.0000000000038448

IF: 1.6

2024-06-09

Medicine

Abstract:The current work aims to evaluate the association between genetic mutations in thymidylate synthetase (TYMS gene in exon1 and partial regions of promotor and intron 1 [877 bp, 657,220–658,096 bp]) and the therapeutic outcomes for rheumatoid arthritis (RA) Iraqi patients. An observational cross-sectional study involving 95 RA patients with established RA patients based on their methotrexate treatment responsiveness. Genetic sequencing of the TYMS gene was performed for all patients according to the instruction manuals of the sequencing company (Macrogen Inc. Geumchen, South Korea). Four polymorphisms were identified by sequencing 95 randomly selected patients in the noncoding region of TYMS. Three of these polymorphisms were found in the NCBI database's dbSNP (rs2853741, rs2606241, and rs2853742 SNPs), and one SNP polymorphism is novel (657334). The CTAT (657334, rs2853741, rs2606241, and rs2853742 SNPs) haplotype was significantly associated with responder with odd ratio, 95% confidence interval: 0.506, 0.281–0.912 (P value = .022). In contrast, the other haplotypes were not associated with MTX responsiveness. In the multivariate analysis, after adjusting to the effect of age, sex, smoking, and disease duration, the TC rs2853741 genotype was associated with non-responders (P value = .030). In contrast, the AC rs260641 genotype, after adjusting to the effect of age, sex, and smoking, was associated with non-responders (P value = .035). Genetic polymorphism of the TYMS gene, especially in TC rs2853741 and AC rs260641 , predicts non-responder to MTX treatment in RA, while the presence of the CTAT haplotype predicts a good response to MTX treatment.

medicine, general & internal
Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients

Dubravka Vejnović,Vera Milić,Branka Popović,Tatjana Damnjanović,Nela Maksimović,Vera Bunjevački,Maja Krajinović,Ivana Novaković,Nemanja Damjanov,Biljana Jekić

DOI: https://doi.org/10.1080/17425255.2019.1563594

2019-01-04

Abstract:BACKGROUND: Methotrexate (MTX), a folate analogue, is the most commonly used disease-modifying drug in the treatment of rheumatoid arthritis (RA). However, high interindividual differences in drug response are present among RA patients.RESEARCH DESIGN AND METHODS: In a group of 234 RA patients treated with MTX, we investigated whether rs1650697 polymorphism in DHFR gene may have an impact on MTX efficacy and/or adverse drug effects (ADEs). Relative DAS28 values (rDAS28) were used for the estimation of MTX therapy and all ADEs were recorded. Patients were genotyped for selected polymorphism by real-time PCR method.RESULTS: According to the European League Against Rheumatism criteria after 6 months of MTX therapy, 196 patients (83.8%) were classified as responders (25 (10.7%) were good and 171 (73.1%) were moderate) and 38 patients (16.2%) as nonresponders. ADEs were observed in 55 patients (23.5%).CONCLUSIONS: Our results showed that the presence of T allele might be protective against MTX hepatotoxicity measured by transaminase levels (p = 0.05). Furthermore, among patients who also received low-dose corticosteroids, we have found a lower rDAS value in patients with CC genotype (p = 0.039).

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients

R J H M van der Straaten,Judith A M Wessels,Jeska K de Vries-Bouwstra,Yvonne P M Goekoop-Ruiterman,Cornelia F Allaart,Judith Bogaartz,Marco Tiller,Tom W J Huizinga,Henk-Jan Guchelaar

DOI: https://doi.org/10.2217/14622416.8.2.141

Pharmacogenomics

Abstract:The enzyme folylpoly-gamma-glutamase synthethase (FPGS) plays an important role in the intracellular polyglutamation of the disease-modifying antirheumatic drug methotrexate (MTX) and the length of the polyglutamated MTX product correlates with the time that MTX resides in the cell. The glutamates are released from MTX by activity of the enzyme gamma-glutamyl-hydrolase (GGH), thereby allowing the efflux of MTX. GGH 452C>T has been associated with decreased catalytic activity and higher accumulation of long-chain MTX-polyglutamate. However, single nucleotide polymorphisms (SNPs) in FPGS and GGH genes have not yet been explored for association with MTX efficacy or toxicity. We selected for SNPs with frequencies higher than 10% or, in case of FPGS 114G>A, causing an amino acid change with no known frequencies. In this study, frequencies of two SNPs in FPGS (1994A>G and 114G>A, rs10106 and rs10760502, respectively) and GGH genes (452C>T and 16T>C, rs11545078 and rs1800909, respectively), were determined using a newly developed method in rheumatoid arthritis patients (n = 352) and in a group of healthy controls (n = 360). Next, the SNPs were associated with response to MTX in rheumatoid arthritis patients treated with MTX monotherapy. In rheumatoid arthritis patients, allele frequencies of FPGS 1994A>G were 0.534 (A) and 0.466 (G), and for FPGS 114G>A 0.714 (G) and 0.286 (A). Allele frequencies of GGH 16T>C were 0.737 (T) and 0.263 (C) and for GGH 452C>T 0.912 (C) and 0.088 (T). No significant differences in allele frequencies between rheumatoid arthritis patients and healthy controls were found. In addition, the SNPs were not associated with good clinical response to MTX. Only patients with the GGH 16C-allele and one or no copies of the GGH 452C-16T haplotype were associated with good clinical improvement at 3 months upon treatment with MTX. No associations with efficacy at 6 months and MTX-induced toxicity were found. Therefore we conclude that despite the positive association of the GGH 16C-allele and one or no copies of the GGH 452C-16T haplotype with good clinical improvement at 3 months upon treatment with MTX, the tested SNPs in GGH and FPGS genes are suggested not to be clinically important for MTX treatment outcome.
Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis

Masakatsu Yanagimachi,Takuya Naruto,Takuma Hara,Masako Kikuchi,Ryoki Hara,Takako Miyamae,Tomoyuki Imagawa,Masaaki Mori,Tetsuji Kaneko,Satoshi Morita,Hiroaki Goto,Shumpei Yokota

DOI: https://doi.org/10.1111/j.1365-2125.2010.03814.x

Abstract:Aims: We investigated whether several polymorphisms within the methotrexate (MTX) pathway genes were related to the toxicity and efficacy of MTX in 92 Japanese patients with articular-type juvenile idiopathic arthritis (JIA). Methods: Eight gene polymorphisms within the MTX pathway genes, namely, RFC, BCRP, MTHFR (two), FPGS, γ-glutamyl hydrolase (GGH; two) and ATIC, were genotyped using TaqMan assays. Liver dysfunction was defined as an increase in alanine transaminase to five times the normal upper limit. Non-responders to MTX were defined as patients refractory to MTX and were therefore treated with biologics. Results: The non-TT genotype at GGH T16C was associated with a high risk of liver dysfunction (P=0.028, odds ratio=6.90, 95% confidence interval 1.38-34.5), even after adjustment for the duration of MTX treatment. A longer interval from disease onset to treatment (8.5 and 21.3 months, P=0.029) and rheumatoid factor positivity (P=0.026, odds ratio=2.87, 95% confidence interval 1.11-7.39) were associated with lower efficacy of MTX. Conclusions: The non-TT genotype at GGH T16C was associated with a high risk of liver dysfunction, presumably because the C allele of GGH C16T may reduce the activity of GGH. The time interval before MTX treatment and rheumatoid factor positivity were associated with the efficacy of MTX treatment. The pharmacogenetics of the MTX pathway genes affects the toxicity and efficacy of MTX in Japanese JIA patients.
Association of the MTHFR Gene Polymorphisms with Efficacy and Toxicity of Methotrexate in Patients with Juvenile Idiopathic Arthritis

Margarita Ganeva,Stefan Stefanov,Albena Teltcharova-Mihaylovska,Reni Tzveova,Radka Kaneva,Radoslava Saraeva,Katya Temelkova

DOI: https://doi.org/10.7546/crabs.2024.01.17

2024-01-29

Proceedings of the Bulgarian Academy of Sciences

Abstract:The aim of this study was to investigate whether the C677T and A1298C polymorphisms of methylenetetrahydrofolate reductase (MTHFR) gene might be related to the prediction of toxicity and efficacy of methotrexate (MTX) in juvenile idiopathic arthritis (JIA) in clinical practice. Sixty-three patients (50 girls and 13 boys) fulfilling the International League of Associations for Rheumatology (ILAR) criteria for JIA were included in the study. Patients were divided into two groups – those undergoing treatment with MTX monotherapy and putative optimal response ($$n = 28$$), and those with poor response to therapy with MTX and therefore shifted to treatment with MTX and a biological agent ($$n = 35$$). DNA for SNP analysis was automatically isolated from whole blood through chemagic Magnetic Separation Module I instrument (PerkinElmer chemagen Technologie GmbH, Baesweiler, Germany). The following SNPs in MTHFR gene – 677C>T (rs1801133) and 1298A>C (rs1801131) – were analyzed using High Resolution Melt (HRM) analysis. A real-time PCR (RotorGene 6000, Qiagen, USA) was performed for amplification of DNA prior to HRM analysis. We did not find any significant difference in the distribution of genotype ($$\chi2 = 1.04$$; df $$= 2/\chi2 = 0.60$$; df = 2) and allele ($$\chi2 = 0.11$$; df = $$1/\chi 2 = 0.03$$; df = 1) frequencies of polymorphisms C677T and A1298C between the two groups. Adverse events (nausea, dizziness, headache, hepatotoxicity) due to MTX were noted among four of the patients. It was found that all of the patients who experienced side effects of the treatment carry the allelic variant C677T (three CT heterozygotes and one TT homozygote). The variant allele A1298C was found in one of these four patients. We did not find any significant association between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate.

multidisciplinary sciences
Genetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis

Alejandro Escudero-Contreras,Clementina López-Medina,Eduardo Collantes-Estévez,Rafaela Ortega-Castro,Jerusalem Calvo-Gutiérrez,Natalia Mena-Vázquez,Blanca Panero-Lamothe,Bárbara Manzanares-Martín,Rafael Cáliz-Cáliz,Alberto Jiménez-Morales,Mayte Ruiz-Jiménez,Pilar Font-Ugalde

DOI: https://doi.org/10.3390/jcm10184070

2021-09-09

Abstract:Objective: to identify new single-nucleotide polymorphisms (SNPs) in genes encoding proteins involved in methotrexate (MTX) metabolism and to evaluate the associations of these SNPs with MTX toxicity or intolerance in a southern Spanish cohort of patients with rheumatoid arthritis (RA). Methods: An observational, retrospective, and multicenter study was conducted at three participating hospitals in southern Spain. The main variable was intolerance to MTX (i.e., bDMARD monotherapy), defined as an interruption of treatment due to adverse events or toxicity. Patients being treated with MTX and bDMARDs (combined treatment) at the time of the study visit were considered "tolerant" of MTX. Ten polymorphisms were selected for sequencing in our patients according to a literature review. Each polymorphism was classified according to three possible genotypes (e.g., two homozygous (AA or GG) and one heterozygous (AG)), and the association of these combinations with MTX intolerance was evaluated. Results: A total of 227 patients were included in the final analysis (107 intolerant of MTX and 120 tolerant). A significant association was observed between MTX intolerance and the GGH-T401C AA/AG genotype (OR 2.13, 95% CI 1.06-4.29) in comparison with the GG genotype. On the other hand, an inverse association was observed between the ABCC2-C24T TT/TC genotype and intolerance to MTX (OR 0.59, 95% CI 0.35-1.00) in comparison with the CC genotype. Conclusion: This study provides new data on the association between genetic polymorphisms and MTX intolerance, which may contribute to the development of new biomarkers and personalized medicine in patients with RA.
[Vitamin E in human nutrition].

R. Nicolaysen

1966-11-17

Abstract:LTHOUGH the existence of vitamin E has been known for approximately 40 years, and vitamin E deficiency states have been induced experimentally in many species, including fish, birds, and mammals, its importance in iluman nutrition is not yet clearly understood. Excellent studies of vitamin E deficiency in the Rhesus monkey by Dinning and Day1 and Finch et al.2 extended the earlier observations of Mason and Telford and Filer and co-workers and are probably predictive of the deficiency syndrome to be found in man. Manifestations of vitamin E deficiency in human subjects consist of decreased concentrations of tocopherol in serum, oxidative hemolysis of erythrocytes, creatinuria, and pathologic changes in certain tissues. Clinical correlates of these laboratory evidences of deficiency have not been detected in human subjects. Seven clinically related compoundsalpha-, beta-, gamma-, delta-, epsilon-, zetaand eta-tocopherol-exert vitamin E activity. Of these, aipha-tocopherol is most potent. Although the only rich sources of tocopherols are some vegetable oils, smaller quantities are present in a wide variety of foods. Tocopherols are important natural antioxidants in foods and are especially effective in preventing oxidation of fats.#{176} Since vitamin E is fat-soluble, it seemed reasonable to seek evidence of human deficiency of vitamin E in individuals with abnormalities in intestinal absorption of fat. In searching for such evidence, Pappenheimer and Victor,#{176} Woodruff, Gordon et al.,8 and Goldbloom9 determined concentrations of tocopherol in plasma or serum of individuals with steatorrhea, studied the extent of its absorption from the
The association between GGH-401C＞T polymorphism and methotrexate efficacy and toxicity in rheumatoid arthritis: a meta-analysis

Li-ping LIU,Yu-tong YIN,Yi-wei LIU,Li-bo ZHAO,Jian GU

DOI: https://doi.org/10.3969/j.issn.1672-3384.2018.02.009

2018-01-01

Abstract:Objective:To evaluate the association of GGH-401C＞T polymorphism with the responsiveness to and toxicity of methotrexate in rheumatoid arthritis with a meta analysis.Methods:CBM,CNKI,VIP,Wanfang,Pubmed,Embase and Cochrane library databases were systematically searched up to November 2017 with two independent reviewers screened the relevant literatures.The studies met our inclusion criteria were included for data extraction and quality assessment.The meta-analysis was conducted with RevMan 5.3 software.Results:A total of 5 studies were included.meta-analysis showed no association between GGH-401C＞T polymorphism and methotrexate responsiveness (OR=0.94,95％CI:0.72～1.21),P=0.61.And no association could be detected in the analysis of MTX-related toxicity (OR=1.19,95％CI:0.92～1.55),P=0.19.However,a marginal power in the dominant model was observed (CC vs CT+TT:OR:1.49,95％CI:0.94～2.36),P=0.09,and when the study of Lima was removed,it showed a statistical significance with OR:2.39,95％CI:1.02～5.59,P=0.05.Conclusion:Our meta-analysis showed no significant association between GGH-401C＞T polymorphism and the efficacy of methotrexate but there was a slight trend that CC genotype might result in a higher incidence of adverse events compared with CT and TT carriers.
Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.

Yu Weng,Jun Zhang,Xue Tang,Xinyou Xie,Guangdi Chen

DOI: https://doi.org/10.3109/10428194.2011.649477

2012-01-01

Leukemia & Lymphoma

Abstract:Previous studies on the association of Thymidylate synthase (TYMS) polymorphisms with risk of hematological malignancies have produced conflicting results. The purpose of this meta-analysis was to define the effect of TYMS 5'-untranslated enhanced region (TSER) and 3'-untranslated region (TS3'-UTR) polymorphisms on the risk of hematological malignancies. Seventeen articles were identified as eligible in the case of TSER (2R > 3R) polymorphism (4511 cases and 6113 controls) and seven articles in the case of TS3'-UTR (1494del6) polymorphism (2721 cases and 3761 controls). The overall results suggested that either TSER or TS3'-UTR polymorphism was not associated with the risk of hematological malignancies. In stratified analyses, significantly decreased acute lymphoblastic leukemia (ALL) risk was found in adults (2R/3R vs. 2R/2R: odds ratio [OR] = 0.64, 95% confidence interval [CI]: 0.43-0.97), but increased ALL risk was observed in children (3R/3R vs. 2R/2R: OR = 1.46, 95% CI: 1.03-2.06). Increased non-Hodgkin lymphoma risk was found in the Caucasian population (2R/3R vs. 2R/2R: OR = 1.31, 95% CI: 1.10-1.56). Protective effects of the TS3'-UTR polymorphism (-6 bp/-6 bp) on hematological malignancies were found in a homozygote model and recessive model when the source of controls was stratified as hospital based. In conclusion, the TYMS TSER polymorphism may contribute to a susceptibility to risk of ALL in children and non-Hodgkin lymphoma in Caucasians, but protection from ALL risk in adults. The TS3'-UTR polymorphism (-6 bp/-6 bp) may have a protective effect in hematological malignancies.
Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome

Aurea Lima,Miguel Bernardes,Rita Azevedo,Vitor Seabra,Rui Medeiros

DOI: https://doi.org/10.2217/pgs-2016-0067

Pharmacogenomics

Abstract:Aim: Evaluate the potential of selected SNPs as predictors of methotrexate (MTX) therapeutic outcome. Patients & methods: In total, 35 SNPs in 14 genes involved in MTX intracellular pathways and Phase II reactions were genotyped in 233 rheumatoid arthritis (RA) patients treated with MTX. Binary logistic regressions were performed by genotype/haplotype-based approaches. Non-Response- and Toxicity-Genetic Risk Indexes (Non-RespGRI and ToxGRI) were created. Results: MTX nonresponse was associated to eight genotypes and three haplotypes: MTHFR rs1801131 AA and rs1801133 TT; MS rs1805087 AA; MTRR rs1801394 A carriers; ATIC rs2372536 C carriers, rs4673993 T carriers, rs7563206 T carriers and rs12995526 T carriers; CC for GGH rs3758149 and rs12681874; CGTTT for ATIC combination 1; and CTTTC for ATIC combination 2. From overall Non-RespGRI patients with indexes 6-8 had more than sixfold increased risk for MTX nonresponse than those patients with indexes 0-5. MTX-related toxicity was associated to five genotypes and two haplotypes: ATIC rs2372536 G carriers, rs3821353 T carriers, rs7563206 CC and rs12995526 CC; ADORA2A rs2267076 T; CTTCC for ATIC combination 1; and TC for ADORA2A rs2267076 and rs2298383. From overall ToxGRI, patients with indexes 3-4 had more than sevenfold increased risk for MTX-related toxicity than those patients with indexes 1-2. Conclusion: Genotyping may be helpful to identify which RA patients will not benefit from MTX treatment and, consequently, important to personalized medicine in RA. Nevertheless, further studies are required to validate these findings.
AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients

Anna Wajda,Ewa Walczuk,Barbara Stypińska,Jakub Lach,Danat Yermakovich,Larysa Sivitskaya,Katarzyna Romanowska-Próchnicka,Tomasz Wysocki,Małgorzata Jarończyk,Agnieszka Paradowska-Gorycka

DOI: https://doi.org/10.1038/s41397-021-00238-4

2021-07-23

The Pharmacogenomics Journal

Abstract:Abstract Methotrexate (MTX) is the first-line therapy for rheumatoid arthritis. Nevertheless, MTX resistance is quite a common issue in clinical practice. There are some premises that aryl hydrocarbon receptor (AhR) gene battery may take part in MTX metabolism. In the present retrospective study, we analyzed genes expression of AHR genes battery associated with MTX metabolism in whole blood of RA patients with good and poor response to MTX treatment. Additionally, sequencing, genotyping and bioinformatics analysis of AHR repressor gene ( AHRR ) c.565C > G (rs2292596) and c.1933G > C (rs34453673) have been performed. Theoretically, both changes may have an impact on H3K36me3 and H3K27me3. Evolutionary analysis revealed that rs2292596 may be possibly damaging. Allele G in rs2292596 and DAS28 seems to be associated with a higher risk of poor response to MTX treatment in RA. RA patients with poor response to MTX treatment revealed upregulated AhR and SLC19A1 mRNA level. Treatment with IL-6 inhibitor may be helpful to overcome the low-dose MTX resistance. Analysis of gene expression revealed possible another cause of poor response to MTX treatment which is different from that observed in the case of acute lymphoblastic leukemia.
Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population

Masayuki Hashiguchi,Mikiko Shimizu,Jun Hakamata,Tomomi Tsuru,Takanori Tanaka,Midori Suzaki,Kumika Miyawaki,Takeshi Chiyoda,Osamu Takeuchi,Jiro Hiratsuka,Shin Irie,Junya Maruyama,Mayumi Mochizuki

DOI: https://doi.org/10.1186/s40780-016-0069-0

2016-12-09

Abstract:Background: Methotrexate (MTX) is currently the anchor drug widely used worldwide in the treatment of rheumatoid arthritis (RA). However, the therapeutic response to MTX has been shown to vary widely among individuals, genders and ethnic groups. The reason for this has been not clarified but it is considered to be partially due to several mechanisms in the cellular pathway of MTX including single-nucleotide polymorphisms (SNPs). The purpose of this study was to investigate the allelic frequencies in different ethnic and/or population groups in the 10 polymorphisms of enzyme proteins and transporters related to the MTX response and pharmacokinetics including MTHFR, TYMS, RFC1, FPGS, GGH, ABCB1, ABCC2 and ABCG2 in unrelated healthy Japanese adults and patients with RA. Methods: Ten polymorphisms, methylenetetrahydrofolate reductase (MTHFR) 1298, thymidylate synthase (TYMS) 3'-UTR, reduced folate carrier 1 (RFC1) 80 and-43, folypolyglutamyl synthase (FPGS) 1994, γ-glutamyl hydrolase (GGH) 452 and-401, the ABC transporters (ABCB1 3435, ABCC2 IVS23 + 56, ABCG2 914) of enzyme proteins and transporters related to MTX response and pharmacokinetics in 299 unrelated healthy Japanese adults and 159 Japanese patients with RA were investigated to clarify their contributions to individual variations in response and safety to MTX and establish personalized MTX therapy. SNPs were evaluated using real-time polymerase chain reaction (PCR). Results: Comparison of allelic frequencies in our study with other ethnic/population groups of healthy adults and RA patients showed significant differences in 10 polymorphisms among healthy adults and 7 among RA patients. Allelic frequencies of MTHFR 1298 C, FPGS 1994A and ABCB1 3435 T were lower in Japanese than in Caucasian populations and those of ABCC2 IVS23 + 56 C and ABCG2 914A were higher in Japanese than in Caucasian/European populations in both healthy adults and RA patients. Allelic frequencies of MTHFR 1298 C, GGH-401 T, ABCB1 3435 T, and ABCG2 914A were higher in healthy Japanese adults than in an African population, and those of RFC1 80A, RFC1-43C and ABCC2 IVS23 + 56 C in healthy Japanese adults were lower than in Africans. However, no significant differences were seen in the distribution of allelic frequencies between healthy Japanese adults and RA patients. Conclusion: The variations in allelic frequencies in different ethnic and/or population groups in healthy adults and RA patients may contribute to individual variations in MTX response and toxicity.
Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients

Patricia Moya,Juliana Salazar,María Jesús Arranz,César Díaz-Torné,Elisabeth del Río,Jordi Casademont,Hèctor Corominas,Montserrat Baiget

DOI: https://doi.org/10.2217/pgs.15.150

Pharmacogenomics

Abstract:Background: Methotrexate (MTX) is the most used drug for the treatment of rheumatoid arthritis (RA) although outcome differs among patients. Aim: To evaluate whether polymorphisms in pharmacokinetic genes are associated with outcome in RA patients receiving MTX. Patients & methods: We analyzed 28 SNPs in SLC19A1/RFC1, ABCB1, FPGS and GGH genes. Results: We studied 194 RA patients receiving MTX monotherapy. Two FPGS SNPs, rs10987742 and rs10106, were associated with response (p = 0.033 and p = 0.041, respectively). The FPGS rs10106 variant was also associated with MTX survival (p = 0.005) and toxicity (p = 0.021). Three ABCB1 SNPs, rs868755, rs10280623 and rs1858923, were associated with toxicity (p = 0.025, p = 0.048 and p = 0.031, respectively). Conclusion: FPGS and ABCB1 genetic variants can influence the outcome in RA patients receiving MTX monotherapy.
MTHFR Gene Polymorphisms in Iraqi Kurdish Rheumatoid Arthritis Patients: Relation to Methotrexate Response and Toxicity

Sherzad Saeed Younis,Najlaa Kadhm Issa,Dhia Mustafa Sulaiman

DOI: https://doi.org/10.24996/ijs.2022.63.12.9

2022-12-30

Iraqi Journal of Science

Abstract:Methotrexate (MTX) is still one of the gold standard treatments for rheumatoid arthritis (RA). It shows diverse outcomes in blood level and clinical response, this was demonstrated by its relation to the genetic polymorphism in the pharmacogenetic study. This study aimed to investigate the role of methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms in relation to MTX efficacy and toxicity in Iraqi Kurdish RA patients. Sixty-four RA patients were involved in this study with an average age of 47.78 ±14.08 and female to male ratio of (8.1). Diagnosis and disease activity were confirmed. Blood analyses, including those of laboratory markers of disease activity, were done. The 28 joint disease activity score (DAS28-CRP) was calculated. MTHFR gene polymorphisms were analyzed by real-time polymerase chain reaction. The most frequent genotypes which were identified in RA patients were the CT genotype of the C677T single nucleotide polymorphism (SNP) (51.6%) and the AC genotype of the A1298C SNP (48.4%). Patients with non-response to treatment had high frequencies of genotypes CT and TT (58.0% and 12.0%) of the C677T SNP respectively, as compared to those in the responder group; 28.6% and 0.0%); T-allele was associated with drug non-responding OR=4.17, P value=.0.009, meanwhile; genotypes AC and CC of the A1298C SNP were seen in (54.0% and 16.0%) in non-responder group. Patients with active RA had increased frequencies of CT and TT genotypes of the C677T SNP (60.0% and16.0%) respectively as compared to those who were in remission (26.6% and 0.0%); T-allele was associated with high disease activity; OR = 5.11. No association was found between C677T SNP and A1298C SNP, and MTX level status (P> 0.05). However, the variant alleles (T and C) were associated with the MTX toxic level (OR: 2.05, 95% CI [0.97 – 4.32]) and (OR: 1.99, 95% CI [0.96 – 4.18]) respectively. This study suggests that genetic polymorphisms of MTHFR SNP (C677T and A1298C) are associated with MTX efficacy but not toxicity in RA patients. This may assist the physicians in personalizing RA treatment in Iraqi patients.
Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis

Masayuki Hashiguchi,Tomomi Tsuru,Kumika Miyawaki,Midori Suzaki,Jun Hakamata,Mikiko Shimizu,Shin Irie,Mayumi Mochizuki

DOI: https://doi.org/10.1186/s40780-016-0047-6

2016-06-07

Abstract:Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by systemic inflammatory status, joint destruction, disability, and pain. Methotrexate (MTX) has been confirmed to reduce disease activity and delay or stabilize the development of bone erosions. However, major drawbacks are that patients show great interindividual variability in response to MTX and the unpredictable occurrence of side effects. A strategy for personalized MTX treatment to predict its efficacy and toxicity has not yet been determined. To establish personalized MTX therapy in Japanese patients with rheumatoid arthritis, we performed a preliminary study for predicting better methotrexate efficacy including single-nucleotide polymorphisms (SNPs) for MTX-related transporters/enzymes. Methods: Disease control status (good or poor) was judged by the number of Disease Activity Scores (DAS28) of <2 for 6-12 months. The response index R was calculated by the improved area under the curve (AUC) of the DAS28 score for 0-3 or 0-6 months by dividing the cumulative dose of MTX during 0-3 or 0-6 months, respectively. Genotyping of alleles of RFC1 80G > A, RFC1 -43 T > C, FPGS 1994G > A, GGH 401C > T, MTHFR 1298A > C, and TYMS 3'-UTR (-6/+6) was performed using the real-time PCR system. Results: Seven of 21 patients were judged as good responders in terms of disease control, and the remainder as poor responders. For 0-3 months after starting MTX administration, the median cumulative dose and improved DAS28 AUC in the good and poor response groups were 96.0 mg and 25.4 and 118.0 mg and 23.4, respectively. For 0-6 months, the median cumulative dose and improved DAS28 AUC in the good and poor response groups were 192.0 mg and 51.0 and 214.0 mg and 47.6, respectively. Statistically significant differences between the 2 groups in the 0-6-month period were observed in DAS28 AUC improvement and index R. A slight tendency for a correlation between G/G genotypes and A allele genotypes in RFC1 80 genotypes was observed, although it did not reach statistical significance. Conclusion: This study suggested that aggressive RA treatment with MTX from the early period of administration is necessary to obtain a good response after 6 months, although no SNPs predicting a better treatment response to MTX were identified.
Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients

Ravi Ramalingam,Harpreet Kaur,Julius Xavier Scott,Latha M. Sneha,Ganeshprasad Arunkumar,Arathi Srinivasan,Solomon F. D. Paul

DOI: https://doi.org/10.1007/s00280-022-04405-7

2022-02-14

Cancer Chemotherapy and Pharmacology

Abstract:PurposePediatric acute lymphoblastic leukemia (pALL) patients have better overall survival and methotrexate (MTX) is an effective drug used in their treatment. However, the treatment-related adverse effects (TRAEs) have a bigger impact on the therapy. In this study, we have evaluated the association of polymorphisms in genes encoding proteins engaged in MTX metabolism, and the cytogenetic aberrations with TRAEs.MethodsA total of 115 patients between the age of 1 and 18 years (average: 6.6) under maintenance therapy were selected for the study. SLC19A1 (c.80G > A), MTHFR (c.677C > T; c.1298A > C), and TYMS (c.*450_*455del) genotypes were determined using PCR techniques and Sanger sequencing. Cytogenetic and SNP findings were analyzed for any association with the reported toxicities using odds ratio, chi-square test, multifactor dimensionality reduction (MDR) analysis for synergistic effect and, multinomial logistic regression analysis for the likelihood of adverse events.ResultsAmong the evaluated genetic variations, SLC19A1 (c.80G > A) was significantly associated with TRAEs (OR = 5.71, p = 0.002). Multinomial logistic regression analysis (chi-sq = 16.64, p < 0.001) and MDR analysis (chi-sq = 10.51 p < 0.001) confirmed the finding. On the other hand, no significant association was observed between adverse events and any specific cytogenetic aberration.ConclusionSLC19A1 facilitates the import of cyclic dinucleotides and reduced folates, evaluating genotypes in this gene can help in better management of patients on methotrexate treatment. Assessing a broader gene panel can help in finding more associated markers and delivering personalized medicine to the patients.

oncology,pharmacology & pharmacy
Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis

Vinod Chandran,Fotios Siannis,Proton Rahman,Fawnda J Pellett,Vernon T Farewell,Dafna D Gladman

DOI: https://doi.org/10.3899/jrheum.091311

Abstract:Objective: To determine the association between folate pathway gene polymorphisms and the effectiveness, toxicity, and drug survival of methotrexate (MTX) in psoriatic arthritis (PsA). Methods: Data were obtained from a longitudinal cohort of PsA patients evaluated according to a standard protocol. Data on duration of drug therapy, dose, side effects, and reasons for discontinuation are systematically recorded. Patients treated with MTX after clinic admission who had > or = 3 swollen joints prior to initiating MTX therapy were selected for evaluation of effectiveness. Response to MTX treatment was assessed at 6 months. Data from all patients treated in the clinic with MTX were used in evaluation of toxicity and drug survival. The following single-nucleotide polymorphisms (SNP) were measured using the Sequenom platform: MTHFR 677C>T (rs1801133), MTHFR 1298A>C (rs1801131), DHFR -473T>C (rs1650697), DHFR 35289A>G (rs1232027), and RFC 80G>A (rs1051266). Fisher's exact test, logistic regression, and Cox proportional hazard analyses were used to determine association. Results: Two hundred eighty-one patients were identified from the database. All patients were included in the analysis for side effects and drug survival, and 119 patients were included in the effectiveness analysis. The minor A allele of DHFR gene at +35289 was the only SNP demonstrating association with response to MTX therapy (OR 2.99, p = 0.02). Patients homozygous for the minor allele of MTHFR 677C/T (677TT) had more liver toxicity (Fisher exact test, p = 0.04). Conclusion: Polymorphisms of the DHFR gene may be associated with MTX efficacy. MTHFR 677TT may have a relationship with MTX-induced liver toxicity in PsA.
Impact of MTHFR C677T and A1298C gene polymorphisms on MTX drug toxicity and efficacy profile of RA patients in North India

Anamika Dwivedi,Abhimanyu Kumar Jha,Varsha Gupta

DOI: https://doi.org/10.1016/j.mgene.2020.100705

2020-06-01

Meta Gene

Abstract:ObjectiveTo investigate the effect of two different methylenetetrahydrofolate (MTHFR) gene loci C677T and A1298C polymorphism on Rheumatoid arthritis (RA) and their association in response to methotrexate (MTX) therapy.Subjects and methods110 individuals (60 RA patients and 50 healthy controls) were enrolled from different regions of north India. MTX drug response was evaluated by questionnaire data analysis, disease activity score (DAS-28) and analysis of hepatic, renal and other serological parameters. MTHFR C677T and A1298C polymorphism were genotyped using restriction fragment length polymorphism- polymerase chain reaction (RFLP-PCR). Independent t-test was applied to compare the means and ANOVA with Bonferroni correction for multiple comparison of genotypically classified groups. The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by applying χ2 test, p-value < .05 was considered significant.ResultsThe study found significant differences in all the serological parameters of controls and RA patients except protein and serum SGPT. Elevated transaminases, triglycerides, cholesterol, creatinine, C-reactive protein (CRP), uric acid and albumin are the indicators of MTX adverse effects along with disease severity. Questionnaire analysis showed loss of appetite, weak digestion, low BMI, and weight loss are common features in all the patients after starting MTX therapy. Significant association was found between 677TT genotype with elevated levels of triglycerides. While other parameters such as SGOT, SGPT, CRP, uric acid and cholesterol are insignificantly higher in patients with 677TT polymorphism. 1298CC polymorphism was associated with high CRP levels and 1298 AC with higher triglycerides along with cholesterol in RA patients. However, in controls, only albumin showed significant association with 1298AA genotype. Association of MTHFR C677T polymorphism was highly insignificant (677CT- OR: 0.905, 95%CI: 0.355–2.307; 677TT- OR: 1.035, 95%CI: 0.338–3.989; p-value = 1) and A1298C polymorphism was also insignificant (1298AC- OR: 0.562, 95%CI: 0.200–1.575, p-value = .4; & 1298CC- OR: 0.502, 95%CI: 0.146–1.717 with p-value = .403) with RA.ConclusionThe results of this study suggest that none of these alleles are predictive for RA disease susceptibility. However, it has a significant impact on its severity with respect to CRP, triglycerides and cholesterol.
The Role of Genetic Polymorphisms in High-Dose Methotrexate Toxicity and Response in Hematological Malignancies: A Systematic Review and Meta-Analysis

Zaiwei Song,Yang Hu,Shuang Liu,Dan Jiang,Zhanmiao Yi,Mason M. Benjamin,Rongsheng Zhao

DOI: https://doi.org/10.3389/fphar.2021.757464

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:Objective: High-dose methotrexate (HDMTX) is a mainstay therapeutic agent for the treatment of diverse hematological malignancies, and it plays a significant role in interindividual variability regarding the pharmacokinetics and toxicity. The genetic association of HDMTX has been widely investigated, but the conflicting results have complicated the clinical utility. Therefore, this systematic review aims to determine the role of gene variants within the HDMTX pathway and to fill the gap between knowledge and clinical practice. Methods: Databases including EMBASE, PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and the Clinical were searched from inception to November 2020. We included twelve single-nucleotide polymorphisms (SNPs) within the HDMTX pathway, involving RFC1, SLCO1B1, ABCB1, FPGS, GGH, MTHFR, DHFR, TYMS, and ATIC. Meta-analysis was conducted by using Cochrane Collaboration Review Manager software 5.3. The odds ratios (ORs) or hazard ratios (HRs) with 95% confidence interval (95% CI) were analyzed to evaluate the associations between SNPs and clinical outcomes. This study was performed according to the PRISMA guideline. Results: In total, 34 studies with 4102 subjects were identified for the association analysis. Nine SNPs involving MTHFR, RFC1, ABCB1, SLCO1B1, TYMS, FPGS, and ATIC genes were investigated, while none of studies reported the polymorphisms of GGH and DHFR yet. Two SNPs were statistically associated with the increased risk of HDMTX toxicity: MTHFR 677C > T and hepatotoxicity (dominant, OR=1.52, 95% CI=1.03-2.23; recessive, OR=1.68, 95% CI=1.10-2.55; allelic, OR=1.41, 95% CI=1.01-1.97), mucositis (dominant, OR=2.11, 95% CI=1.31-3.41; allelic, OR=1.91, 95% CI=1.28-2.85), and renal toxicity (recessive, OR=3.54, 95% CI=1.81-6.90; allelic, OR=1.89, 95% CI=1.18-3.02); ABCB1 3435C > T and hepatotoxicity (dominant, OR=3.80, 95% CI=1.68-8.61), whereas a tendency toward the decreased risk of HDMTX toxicity was present in three SNPs: TYMS 2R > 3R and mucositis (dominant, OR=0.66, 95% CI=0.47-0.94); RFC1 80A > G and hepatotoxicity (recessive, OR=0.35, 95% CI=0.16-0.76); and MTHFR 1298A > C and renal toxicity (allelic, OR=0.41, 95% CI=0.18-0.97). Since the data of prognosis outcomes was substantially lacking, current studies were underpowered to investigate the genetic association. Conclusions: We conclude that genotyping of MTHFR and/or ABCB1 polymorphisms prior to treatment, MTHFR 677C > T particularly, is likely to be potentially useful with the aim of tailoring HDMTX therapy and thus reducing toxicity in patients with hematological malignancies.

Differential expression of IFN-γ, IL-4, IL-10, and IL-1β mRNAs in decalcified tissue sections of mouse lipopolysaccharide-induced periodontitis mandibles assessed by in situ hybridization

Influence of C677T Polymorphism of 5,10-Methylenetetrahydrofolate Reductase on Methotrexate Toxicity

Impact of TYMS gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients – identification of novel single nucleotide polymorphism: Cross-sectional study

Association of C35T polymorphism in dihydrofolate reductase gene with toxicity of methotrexate in rheumatoid arthritis patients

Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients

Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis

Association of the MTHFR Gene Polymorphisms with Efficacy and Toxicity of Methotrexate in Patients with Juvenile Idiopathic Arthritis

Genetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis

[Vitamin E in human nutrition].

The association between GGH-401C＞T polymorphism and methotrexate efficacy and toxicity in rheumatoid arthritis: a meta-analysis

Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.

Moving toward personalized medicine in rheumatoid arthritis: SNPs in methotrexate intracellular pathways are associated with methotrexate therapeutic outcome

AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients

Genetic polymorphisms of enzyme proteins and transporters related to methotrexate response and pharmacokinetics in a Japanese population

Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients

MTHFR Gene Polymorphisms in Iraqi Kurdish Rheumatoid Arthritis Patients: Relation to Methotrexate Response and Toxicity

Preliminary study for predicting better methotrexate efficacy in Japanese patients with rheumatoid arthritis

Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients

Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis

Impact of MTHFR C677T and A1298C gene polymorphisms on MTX drug toxicity and efficacy profile of RA patients in North India

The Role of Genetic Polymorphisms in High-Dose Methotrexate Toxicity and Response in Hematological Malignancies: A Systematic Review and Meta-Analysis